From: The Medical Malpractice and Personal Injury Blog

Tigecycline (Tygacil) has received an updated warning label from the Food and Drug Administration.  The new label states that alternatives to Tygacil should be considered in treating serious infections due to Tygacil’s increased risk of mortaility in comparison with other antibiotics in treating infections.

According to an FDA safety alert, “alternatives to Tygacil should be considered in patients with severe infections.”

Click on the links for more information.

Relevant Nexreg Compliance Links: CPSC compliance, OSHA MSDS authoring, MSDS authoring